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Abstract
HIV-1 Viral protein R (Vpr) induces a cell cycle arrest at the G2/M phase by activating the ATR DNA damage/stress
checkpoint. Recently, we and several other groups showed that Vpr performs this activity by recruiting the DDB1-CUL4A
(VPRBP) E3 ubiquitin ligase. While recruitment of this E3 ubiquitin ligase complex has been shown to be required for G2
arrest, the subcellular compartment where this complex forms and functionally acts is unknown. Herein, using
immunofluorescence and confocal microscopy, we show that Vpr forms nuclear foci in several cell types including HeLa cells
and primary CD4+ T-lymphocytes. These nuclear foci contain VPRBP and partially overlap with DNA repair foci components
such as c-H2AX, 53BP1 and RPA32. While treatment with the non-specific ATR inhibitor caffeine or depletion of VPRBP by
siRNA did not inhibit formation of Vpr nuclear foci, mutations in the C-terminal domain of Vpr and cytoplasmic
sequestration of Vpr by overexpression of Gag-Pol resulted in impaired formation of these nuclear structures and defective
G2 arrest. Consistently, we observed that G2 arrest-competent sooty mangabey Vpr could form these foci but not its G2
arrest-defective paralog Vpx, suggesting that formation of Vpr nuclear foci represents a critical early event in the induction
of G2 arrest. Indeed, we found that Vpr could associate to chromatin via its C-terminal domain and that it could form a
complex with VPRBP on chromatin. Finally, analysis of Vpr nuclear foci by time-lapse microscopy showed that they were
highly mobile and stable structures. Overall, our results suggest that Vpr recruits the DDB1-CUL4A (VPRBP) E3 ligase to these
nuclear foci and uses these mobile structures to target a chromatin-bound cellular substrate for ubiquitination in order to
induce DNA damage/replication stress, ultimately leading to ATR activation and G2 cell cycle arrest.
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Introduction
HIV-1 encodes several proteins termed accessory that have
been implicated in the modulation of host cell environment to
promote efficient viral replication and evasion from innate and
acquired immunity [1]. One of these accessory proteins, viral
protein R (Vpr), is a small amphipathic protein of 96 amino acids.
In addition to being expressed in infected cells, Vpr is packaged
into virions through an interaction with the p6 domain of the Gag
polyprotein precursor [2,3,4]. The molecular structure of Vpr was
recently resolved and found to consist of a hydrophobic core
comprising three interacting alpha helices flanked by N- and C-
terminal flexible domains [5]. Of note, the third alpha helix
includes a leucine-rich region essential for the stability of the core
and the flexible C-terminus comprises a functionally important
stretch of positively charged arginine residues [6]. Several
biological functions have been attributed to Vpr including
transactivation of the viral long terminal repeat (LTR), enhance-
ment of infection in macrophages, induction of apoptosis, and
promotion of a cell cycle arrest at the G2/M phase [7].
Vpr-mediated G2 arrest likely plays an important role in vivo for
viral replication or pathogenesis given that this activity is highly
conserved among primate lentiviruses [8,9] and since abnormal
accumulation of cells in G2/M can be observed in HIV-infected
individuals [10]. Indeed, recent studies reported that Vpr
upregulated the expression of ligands for the activating NKG2D
receptor and promoted natural killer (NK) cell-mediated killing by
a process that relied on Vpr ability to induce a G2 arrest, thus
suggesting an immunomodulatory role for Vpr that may not only
contribute to HIV-1-induced CD4+ T-lymphocyte depletion but
may also take part in HIV-1-induced NK cell dysfunction [11,12].
Several investigators have reported that Vpr-induced cell cycle
arrest involves the activation of the ATR (ataxia telangiectasia-
mutated and Rad3-related; NM_001184)-mediated G2/M check-
point [10,13,14]. ATR is a kinase of the phosphatidylinositol 3
kinase-like family and is involved in the activation of the G2/M
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occurrence of DNA damages or DNA replication stress. Activation
of ATR by exogenous DNA damaging agents such as UV leads to
phosphorylation of several effector molecules, including Chk1 and
H2AX (histone 2A, variant X; NM_002105), inducing the
formation of DNA repair foci containing c-H2AX (phosphorylat-
ed H2AX), MDC1 (mediator of DNA damage checkpoint 1),
53BP1 (p53 binding protein 1; NM_001141979), BRCA1 (breast
cancer 1), as well as the RPA (replication protein A), 9-1-1 (Rad9-
Hus1-Rad1), and Rad17 complexes on the sites of DNA damage
[15,16]. Activation of ATR by Vpr similarly leads to phosphor-
ylation of Chk1 and to the formation of DNA repair foci
containing c-H2AX, 53BP1, RPA, Hus1, Rad17, and BRCA1
[13,14,17,18]. The immediate cause of the activation of ATR
following Vpr expression has remained elusive but implicates in
part the recruitment by Vpr of the host DDB1 (damage DNA
binding protein 1; NM_001923)-CUL4A (cullin 4A; NM_003589)
E3 ubiquitin ligase complex via a direct binding to the substrate
specificity receptor VPRBP (Vpr-binding protein, also known as
DCAF1; NM_014703) [19,20,21,22,23,24,25]. Specifically, RNA
interference-mediated depletion of VPRBP or mutations in the
hydrophobic leucine-rich core domain of Vpr impaired association
to the E3 ligase complex and induction of G2 arrest. In contrast,
G2 arrest-defective mutants of Vpr in the C-terminal arginine-rich
domain, which maintained their association to the E3 ligase,
nevertheless failed to induce G2 arrest [19,20,21,22,23,24,25].
These results indicate that association of Vpr to the E3 ligase
complex is required but not sufficient to induce G2 arrest, thus
supporting a model in which Vpr would act as a connector
between a ubiquitin ligase complex and a yet-unknown cellular
protein. We recently provided evidence that Vpr-induced K48-
polyubiquitination and proteasomal degradation of this protein(s)
would lead to DNA damage/stress, activation of ATR, and
ultimately G2 cell cycle arrest [26]. HIV-2 and some species of
simian immunodeficiency virus (SIV) encode a paralog of Vpr,
called Vpx, which does not induce G2/M arrest but instead
counteracts a putative restriction factor expressed in macrophages
and dendritic cells that affects infection at a post-entry step [1].
Interestingly, Vpx also interacts with DDB1-CUL4A (VPRBP) via
its hydrophobic leucine-rich core domain. This association is
required for the inactivation of the restriction factor and probably
leads to its proteasomal degradation [27,28,29].
The subcellular localization of Vpr and its importance for the
induction of G2 arrest has remained a source of controversy.
Several investigators reported that Vpr expressed in absence of
any other viral proteins primarily localized to the nucleus in a
diffuse pattern [30,31,32,33,34,35,36] while others observed a
significant accumulation at the nuclear envelope [37,38,39,40,
41,42]. Of note, Sherman et al. showed that Vpr shuttles between
the cytoplasm and nucleoplasm [43]. Moreover, Vpr has been
shown to form punctuate structures in the nucleus [17] as well as
to induce and co-localize with nuclear membrane herniations [44].
C-terminal mutations impairing G2 arrest did not alter localiza-
tion of Vpr whereas other mutations, predominantly in the first
alpha-helix, impaired both nuclear localization and G2 arrest,
implying that nuclear/nuclear-envelope localization of Vpr would
be required but not sufficient for this activity [33,38]. In
agreement with this model, Lai et al showed that nuclear
punctuate structures formed by Vpr were associated to chromatin
and partially co-localized with c-H2AX, suggesting that Vpr might
target host cell DNA and interfere with DNA replication [17]. In
contrast, the F34I, V57L, R62P, L68S, and I70S mutations in Vpr
caused a re-localization of the protein to the cytoplasm without
significantly affecting the induction of G2 arrest [30,36,37,41].
Although inconsistent results were also obtained for some of these
mutants [38], these data would suggest instead that Vpr does not
induce G2 arrest from the nucleus but from an extra-nuclear
compartment.
Therefore, the spatial prerequisites for the induction of Vpr-
mediated G2 arrest remain unclear. Additionally, while recruit-
ment of the DDB1-CUL4A (VPRBP) E3 ubiquitin ligase complex
has been shown to be critical for G2 arrest, the subcellular
compartment where this association occurs and becomes func-
tionally relevant is still unknown. We thus sought to locate the
Vpr-VPRBP interaction and to determine the relevance of this
localization for the induction of G2 arrest with the goal of
furthering our understanding of the mechanism underlying Vpr
activation of ATR and providing important information on the
potential substrate targeted by Vpr. Herein, we show that Vpr
forms nuclear foci that contain VPRBP and that partially co-
localize with DNA repair foci components, such as c-H2AX,
RPA32 (replication protein A2, 32kD; NM_002946) and 53BP1.
Moreover, we provide evidence that formation of these Vpr
nuclear foci constitute a critical early event in the induction of G2
arrest. We also show that Vpr associates to chromatin via its C-
terminal domain and that it binds VPRBP on chromatin. Finally,
we observed that Vpr foci were highly mobile nuclear bodies. Our
results suggest that Vpr recruit the DDB1-CUL4A (VPRBP) E3
ubiquitin ligase complex within mobile nuclear structures to target
a chromatin-bound substrate whose ubiquitination and proteolysis
would activate ATR and induce G2 arrest.
Results
HIV-1 Vpr forms nuclear foci containing VPRBP
The interaction between Vpr and VPRBP was previously
revealed to be required for the induction of a G2 cell cycle arrest
[19,20,21,22,23,24,25]. However, the subcellular localization
where this event might take place still remains to be determined.
To this end, we performed laser-scanning confocal fluorescence
immunohistochemistry to identify the respective subcellular
localization and potential co-localization of Vpr and VPRBP.
Author Summary
HIV-1, the causative agent of AIDS, encodes several
proteins termed accessory, which play a critical role in
viral pathogenesis. One of these accessory proteins, viral
protein R (Vpr), has been found to block normal cell
division. This impairment of cell division by Vpr is thought
to increase viral replication and to trigger immune cell
death. However, how Vpr is able to block cell growth
remains unknown. We and other investigators recently
showed that Vpr was performing this activity by interact-
ing with a cellular protein complex involved in ubiquitina-
tion. Ubiquitination is characterized by the conjugation of
a small protein called ubiquitin to various other proteins to
regulate their degradation or activities. In this report, we
demonstrate that Vpr forms mobile punctuate structures
called foci on the DNA of host cells. We also show that
formation of these foci by Vpr is required to block cell
division. We propose that Vpr recruits the ubiquitination
complex to these nuclear foci and uses these mobile
structures to target a DNA-bound cellular protein for
degradation, resulting in the activation of a host cell
response leading to a cell division block. Identification of
the unknown cellular factor targeted by Vpr will contribute
to the understanding of the role of Vpr during HIV
infection and AIDS pathogenesis.
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HA-tagged Vpr (HA-Vpr) and GFP or a control lentiviral vector
expressing GFP alone. Forty-eight hours after transduction, cells
were fixed, permeabilized and stained with antibodies against HA,
VPRBP, and nucleoporin. The localization of HA-Vpr was mostly
diffuse in the nucleus at standard amplification gain (data not
shown). However, when the gain was reduced, we could observe
that HA-Vpr formed small circular nuclear structures of variable
relative sizes that we refer to thereafter as Vpr nuclear foci (VNF)
(Figure 1A). The number of Vpr nuclear foci varied from cell to
cell and from experiment to experiment but generally averaged 35
foci (SD610) per cell. Formation of these foci was not due to the
HA tag because we observed that native Vpr could also form
nuclear foci (Figure S1A). Endogenous VPRBP was found to be
mostly localized to the nucleus in a punctuate pattern (Figure 1A).
We observed that HA-Vpr colocalized with endogenous VPRBP
in the nucleus. Strikingly, a significant fraction but not all of Vpr
nuclear foci co-localized with VPRBP foci, suggesting that Vpr
might be able to recruit the E3 ubiquitin ligase complex to these
discreet structures. Of note, in presence of Vpr, we also observed
some nuclear membrane perturbations reminiscent of the
previously described Vpr-induced membrane herniations [44].
Importantly, transduction of activated primary CD4+ T-lympho-
cytes with a lentiviral vector expressing HA-Vpr also resulted in
the formation of Vpr nuclear foci that co-localized with VPRBP
(Figure 1B), indicating that these foci are not solely the result of
overexpression of Vpr in transformed cell lines but that their
formation also occurs in a physiological cellular host of HIV.
Infection of HeLa cells with a VSV-G- pseudotyped virus
expressing HA-Vpr (HxBru HA-Vpr) also resulted in the
formation of Vpr nuclear foci in a minor fraction of cells (Figure
S1B). However, the majority of cells displayed a relocalization of
HA-Vpr to cytoplasmic compartments (Figure S1B), suggesting
that formation of these foci would be a dynamic process, regulated
over time during the infection cycle. Indeed, preventing Vpr
interaction with Gag and subsequent packaging of the protein into
virions using mutations in the p6 domain of Gag (LF/PS) or in
Vpr (L23F) [2,32], resulted in the accumulation of Vpr nuclear
foci (Figure S1C). These results provide evidence of the dynamic
interplay between Vpr nuclear foci and Gag during infection.
To show that the observed co-localization between Vpr and
VPRBP foci was not fortuitous and that Vpr foci truly contained
VPRBP, we used an in situ proximity ligation assay (PLA) [45].
This assay is based on the ligation of antibody-coupled DNA
molecules when these are in close proximity (when secondary
antibodies are less than 400 angstro ¨ms apart). Amplification of
ligation products and hybridization with fluorochrome-labelled
probes allow the detection of physiological interaction in situ
without the need to overexpress proteins fused to fluorescent
markers. Using this technique, HA-Vpr was found in close
proximity to endogenous VPRBP in dense nuclear foci (Figure 1C).
We did not observe similar interactions in mock-transfected cells
(Figure S2), in cells expressing a Vpr mutant (Q65R) impaired for
its interaction with VPRBP [19,20,22] (Figure S2), or when any of
the primary antibodies where omitted (data not shown). These
results therefore suggest that Vpr forms nuclear foci containing
VPRBP.
Vpr nuclear foci partially co-localize with DNA repair foci
components
To investigate the nature and composition of these Vpr nuclear
foci, we first evaluated whether these would correspond to known
well-defined nuclear bodies with similar sizes and numbers. We
did not however find any significant co-localization with the
canonical nuclear speckle marker SC35 (also known as SFRS2) or
with PML (promyelocytic leukemia) bodies (Figure S3). Lai et al.
previously reported formation and partial co-localization of Vpr
nuclear foci with c-H2AX [17]. We thus evaluated if the Vpr
nuclear foci described herein where the same foci that Lai et al.
reported. Interestingly, we observed a partial co-localization
between HA-Vpr nuclear foci and 53BP1 (Figure 2A). Indeed,
expression of HA-Vpr induced the re-localization of 53BP1 from
its sites of residence in the nucleus to DNA repair foci, some of
which were positive for HA-Vpr foci. We also observed a partial
co-localization between some HA-Vpr nuclear foci and phosphor-
ylated RPA32 (Figure 2B). Similar results were obtained for c-
H2AX (Figure S4A).
Formation of Vpr nuclear foci represents a critical early
event in Vpr-mediated G2 arrest
Co-localization of Vpr with components of DNA repair foci
suggest that formation of Vpr nuclear foci might represent an early
event in the induction of G2 arrest that would be responsible for
the generation of DNA replication stress or DNA damage.
Conversely, those might simply reflect the re-organization of the
nuclear compartment following the activation of the ATR
checkpoint by Vpr. To distinguish between these two possibilities,
we transduced HeLa cells with a lentiviral vector expressing HA-
Vpr and concomitantly treated the cells with caffeine, a non-
specific inhibitor of ATR and ATM (ataxia telangiectasia
mutated). In these conditions, the addition of caffeine inhibited
Vpr-induced cell cycle arrest (data not shown; [12]). However, we
did not detect significant changes in the number of Vpr nuclear
foci (Figure 3A, 33610 for non-treated cells vs 3269 for caffeine-
treated cells), suggesting that formation of these foci would take
place independently of the activation of ATR. Moreover,
consistent with the observation that not all Vpr nuclear foci co-
localized with VPRBP (Figure 1A), depletion of VPRBP by siRNA
(95%63.5% knockdown relative to scrambled siRNA) in HeLa
cells (Figure 3B) did not significantly alter the number of foci
(36610 for control siRNA vs 3368 for VPRBP siRNA)
(Figure 3C), suggesting that VPRBP is dispensable for the
formation of Vpr nuclear foci. Similar results (data not shown)
were obtained in a HEK293T monoclonal cell line stably depleted
of VPRBP [26]. Moreover, in contrast to its absence of effect on
Vpr foci, knockdown of VPRBP abrogated Vpr-induced forma-
tion of DNA repair foci containing c-H2AX and 53BP1 (Figures
S4A and S4B). These results indicate that Vpr forms nuclear foci
prior to and independently of the activation of ATR and suggest
that it is Vpr that recruits VPRBP to these foci and not the inverse.
To evaluate the potential role of these Vpr nuclear foci in the
induction of G2 arrest, we monitored the capacity of several G2
arrest-defective Vpr mutants to form these foci. HeLa cells were
transfected with plasmids expressing HA-tagged Vpr mutants and
formation of nuclear foci was evaluated by fluorescence immuno-
histochemistry and confocal microscopy (Figure 4). We found that
Vpr (R80A), which still interacts with the E3 ligase but is strongly
attenuated for the induction of G2 arrest, was defective for the
formation of nuclear foci (2.561.1), even though its subcellular
localization was nuclear. Deletion of the C-terminus of Vpr (Vpr
1–78), which also maintains the association with the E3 ligase [22]
but impairs the induction of G2 arrest [46], similarly resulted in a
defect in the formation of nuclear foci (Figure 4). Similar results
were also obtained with the C-terminal mutants Vpr (S79A) and
Vpr (1–86) (data not shown). Vpr (Q65R), which is unable to
associate with the E3 ligase and is consequently defective for G2
arrest, was found to be defective for the formation of nuclear foci
and also accumulated in cytoplasmic aggregates. Similar localiza-
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also defective for its interaction with VPRBP [21] (data not
shown). The results obtained with the Q65R and H71R mutations
are in contrast with the siRNA-mediated depletion of VPRBP
which did not block the formation of Vpr nuclear foci, suggesting
that these mutant proteins might have additional defects besides
an impaired interaction with VPRBP (see below). These results
thus suggest that the C-terminal domain of Vpr, which is required
for the induction of G2 arrest, is also critical for the formation of
Vpr nuclear foci.
The observation that C-terminal G2 arrest-defective mutants of
Vpr are compromised in their capacity to form nuclear foci
suggests that these nuclear foci might constitute an important early
event in the induction of G2 arrest by Vpr. To directly address this
possibility, we first evaluated the functional effect of artificially
sequestering Vpr in the cytoplasm by overexpression of Gag-Pol.
Co-transfection of HeLa cells with HA-Vpr- and Gag-Pol-
expressing plasmids produced a sequestration of HA-Vpr in p24-
positive cytoplasmic compartments (Figure 5A). This sequestration
abrogated Vpr nuclear foci formation (Figure 5A). Similar results
were obtained in HEK293T cells (data not shown). To evaluate
the functional effect of this cytoplasmic sequestration of Vpr,
HEK293T cells were co-transfected with plasmids expressing HA-
Vpr and Gag-Pol or with adequate empty plasmid controls. Two
days later, the cell cycle and expression profiles of transfected cells
were evaluated by flow cytometry and western blot (Figures 5B
and 5C). Expression of HA-Vpr alone produced an accumulation
of cells in G2/M (G2+M:G1=1.81 vs 0.66 for mock-transfected
cells). Interestingly, overexpression of Gag-Pol completely abro-
gated HA-Vpr-induced G2 arrest (G2+M:G1=0.67) in absence of
any significant effect on the cell cycle when expressed alone
(G2+M:G1=0.77). Inhibition of Vpr-induced G2 arrest by
overexpression of Gag-pol was dependent on the Gag-Vpr
interaction and was not the result of some non-specific effects on
the cell cycle since Vpr (L23F), a mutant of Vpr unable to bind the
p6 domain of Gag [2], could form nuclear foci (Figure S5A) but
was impervious to the effect of Gag-Pol on Vpr nuclear
localization (Figure S5B) and induction of G2 arrest (Figure
S5C). Although overexpression of Gag-Pol led to a reduction of
the affinity between HA-Vpr and endogenous VPRBP, the overall
increase in the expression of HA-Vpr resulted in an increase in the
levels of Vpr-bound VPRBP (Figure 5D), excluding the possibility
that overexpression of Gag-Pol inhibited G2 arrest by preventing
the Vpr-VPRBP interaction. The observed inhibition of G2 arrest
by overexpression of Gag-Pol is however unlikely to have a
significant role at physiological levels of expression given that
infection with a wild type virus led to a G2 arrest that was as
efficient as the one obtained with a virus unable to relocalize Vpr
from the nucleus because of a mutation in the P6 domain of Gag
(LF/PS) (Figures S1C and S5D). Overall, these results imply that
nuclear localization of Vpr and possibly the formation of nuclear
foci would be required for the induction of G2 arrest.
To further show that the formation of these Vpr nuclear foci is
critical for the induction of G2 arrest, we evaluated the capacity of
SIV Vpr and its paralog Vpx to form these foci. Both of these
proteins are able to associate with the E3 ligase complex but in
contrast to Vpr, Vpx does not induce G2 arrest but counteract a
putative restriction factor in macrophages and dentritic cells
[27,28,29]. HeLa cells were transfected with plasmids expressing
either HA-tagged sooty mangabey Vpr (HA-Vpr sm) or Vpx (HA-
Vpx sm). Two days after transfection, cells were fixed, permea-
bilized, and stained with antibodies against HA and nucleoporin
(Figure 6). Consistent with its ability to induce G2 arrest (data not
shown and [9]), we found that Vpr sm could accumulate into
nuclear foci (1664 foci per cell) in contrast to the G2-arrest
incompetent Vpx that did not form any foci despite being present
in the nucleus (Figure 6).
Taken together, these results indicate that formation of Vpr
nuclear foci is an early event that is required to induce G2 arrest.
These results also indicate that nuclear localization of Vpr is not
sufficient to induce formation of foci.
Vpr oligomerization is not sufficient to induce foci
formation
Given that these foci constitute an early event in the induction
of G2 arrest, we sought to determine how they would form. These
foci are likely the results of a local observable accumulation of Vpr
either through oligomerization of the protein or following its
recruitment by a locally abundant tethering factor. To distinguish
between these two possibilities, we first monitored the dimerization
efficiency of the Vpr mutants Q65R and R80A, which are
defective for foci formation. HEK293T cells were co-transfected
with plasmids expressing enhanced yellow fluorescence protein
(eYFP) fused to the N-terminus of wild type Vpr and renilla
luciferase (Rluc) fused to the N-terminus of wild type Vpr and
mutants. Two days after transfection, self-affinity was assessed by
bioluminescence resonance energy transfer (BRET). Figure 7A
reveals that all Vpr fusion proteins were efficiently expressed. In
this system, we observed a specific energy transfer between eYFP-
Vpr (WT) and Rluc-Vpr (WT) (Figure 7B). The maximum energy
transfer at saturation (BRETmax) was 0.983 and the concentration
of acceptor at 50% of BRETmax (BRET50) was 0.397. In contrast,
co-expression of eYFP and Rluc-Vpr did not lead to any
significant energy transfer, demonstrating the specificity of the
eYFP-Vpr/Rluc-Vpr interaction. The Q65R mutant, showed a
significant decrease in its affinity for wild type eYFP-Vpr
(BRET50=0.791, 50% self-affinity) as well as a drastic decrease
in BRETmax (0.314 for Q65R vs 0.983 for wild type Vpr),
suggesting that in addition to a reduction in dimerization
efficiency, formation of higher-order complexes (multimerization)
would also be synergistically decreased. In contrast, the R80A
mutant displayed an affinity for wild type Rluc-Vpr that was at
least comparable to wild type Vpr (BRET50=0.326, 121% self-
affinity relative to wild type). Similar results were obtained when
eYFP-Vpr R80A and Rluc-Vpr R80A were co-expressed (data not
shown). Thus, these results suggest that the ability of Vpr to
oligomerize does not directly correlate with nuclear foci formation
and does not explain the defect in foci formation observed in the
Figure 1. HIV-1 Vpr forms nuclear foci containing VPRBP. A) HeLa cells were transduced with lentiviral vectors expressing GFP (WPI) or co-
expressing GFP and HA-tagged Vpr (WPI-HA-Vpr) at a multiplicity of infection of 0.5. B) Primary activated CD4+ T-lymphocytes were transduced by
spinoculation with WPI or WPI-HA-Vpr at a multiplicity of infection of 2.5. For both panels, two days after transduction, cells were fixed,
permeabilized, and stained with antibodies against HA (red), nucleoporin (blue) and VPRBP (green). Images were acquired by confocal microscopy
with a 636objective. Images shown are representative of multiple fields. Enlarged (36) images are shown below panels. Yellow arrows highlight
examples of punctuate co-localization. C) HeLa cells were transfected with a plasmid expressing HA-Vpr. In situ proximity ligation assay (PLA) was
performed on HeLa cells stained with a mouse monoclonal antibody against HA and a rabbit polyclonal antibody against VPRBP. A flurochrome-
labeled probe (red) was then used to reveal locations of close proximity between the two proteins. Hoechst 33342 was used to highlight nuclei
(cyan). Images were acquired by confocal microscopy with a 636objective. Images shown are representative of multiple fields.
doi:10.1371/journal.ppat.1001080.g001
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PLoS Pathogens | www.plospathogens.org 5 September 2010 | Volume 6 | Issue 9 | e1001080Figure 2. Vpr nuclear foci co-localizes partially with DNA repair foci. HeLa cells were transduced with lentiviral vectors expressing GFP (WPI)
or co-expressing GFP and HA-tagged Vpr (WPI-HA-Vpr) at a multiplicity of infection of 0.5. Two days after transduction, cells were fixed,
permeabilized, and stained with antibodies against HA (red) and with either rabbit polyclonal antibodies against 53BP1 (green) (A) or phospho-
RPA32 (green) (B). Images were acquired by confocal microscopy. Images shown are representative of multiple fields. Enlarged (36) images are
shown below panels. Yellow arrows highlight examples of punctuate co-localization.
doi:10.1371/journal.ppat.1001080.g002
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PLoS Pathogens | www.plospathogens.org 6 September 2010 | Volume 6 | Issue 9 | e1001080Figure 3. Formation of Vpr nuclear foci is independent of ATR activation and of the recruitment of VPRBP. A) HeLa cells were pre-
treated with 2.5 mM caffeine for 1 hour and then transduced with lentiviral vectors co-expressing GFP and HA-Vpr (WPI-HA-Vpr) or expressing GFP
alone (WPI). One day after transduction, cells were fixed, permeabilized, and stained with antibodies against HA (red) and nucleoporin (blue). Images
were acquired by confocal microscopy. Images shown are representative of multiple fields. Averages of the number of Vpr nuclear foci (VNF) per cell
and corresponding standard deviations are shown. B) HeLa cells were transfected with control scrambled siRNA or siRNA targeting VPRBP. Forty-
eight hours after transfection, cells were lysed and expression of VPRBP was monitored by western blot. VPRBP and actin were detected using rabbit
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Vpr could still be involved in formation of Vpr nuclear foci, we
performed trans-complementation experiments in HeLa cells and
monitored formation of Vpr foci by immunofluorescence confocal
microscopy. Trans-complementation of HA-Vpr R80A with
eYFP-Vpr could rescue the defective phenotype of the R80A
mutant by re-localizing the protein to eYFP-Vpr foci (Figure 7C).
In contrast, eYFP-Vpr was unable to re-localize the HA-tagged
Q65R mutant (Figure 7C), suggesting that oligomerization of Vpr,
although not sufficient to induce formation of Vpr foci, may
however contribute to the process to some degree.
Association of Vpr to chromatin correlates with
formation of nuclear foci
Since oligomerization does not fully account for the ability of
Vpr to form foci, Vpr could thus be tethered to specific sites by a
Figure 4. Analysis of the capacity of Vpr mutants to form nuclear foci. HeLa cells were transfected with plasmids expressing HA-tagged Vpr
(WT), Vpr (Q65R), Vpr (R80A), and Vpr (1–78). Forty-eight hours after transfection, cells were fixed, permeabilized, and stained with antibodies against
HA (red), nucleoporin (blue) and VPRBP (green). Images were acquired by confocal microscopy. Images shown are representative of multiple fields.
Averages of the number of Vpr nuclear foci (VNF) per cell and corresponding standard deviations are shown.
doi:10.1371/journal.ppat.1001080.g004
polyclonal antibodies. Levels of VPRBP were monitored by computer-assisted densitometry and normalized for actin levels. The means (expressed as
percentage relative to levels of VPRBP in scrambled siRNA-transfected cells (100%)) of three independent experiments are depicted in the graph on
the right panel. C) HeLa cells were transfected with control scrambled siRNA or siRNA targeting VPRBP. Twenty-four hours after transfection, cells
were transduced with lentiviral vectors co-expressing GFP and HA-Vpr (WPI-HA-Vpr) or expressing GFP alone (WPI). One day after transduction, cells
were fixed, permeabilized, and stained with antibodies against HA (red), nucleoporin (blue) and VPRBP (green). Images were acquired by confocal
microscopy. Images shown are representative of multiple fields. Averages of the number of Vpr nuclear foci (VNF) per cell and corresponding
standard deviations are shown.
doi:10.1371/journal.ppat.1001080.g003
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PLoS Pathogens | www.plospathogens.org 8 September 2010 | Volume 6 | Issue 9 | e1001080Figure 5. Cytoplasmic sequestration of Vpr abrogates foci formation and G2 arrest. A) HeLa cells were co-transfected with the packaging
plasmid psPAX2 encoding Gag-Pol, Tat, and Rev and with a HA-Vpr-expressing plasmid or appropriate empty plasmid control. Two days after
transfection, cells were fixed, permeabilized, and stained with antibodies against HA (red), nucleoporin (blue) and p24 (green). Images were acquired
by confocal microscopy. Images shown are representative of multiple fields. B) HEK293T cells were co-transfected with plasmids expressing GFP, HA-
Vpr and Gag-Pol (psPAX2) or with an empty plasmid control as indicated. Forty-eight hours after transfection, cell cycle analysis was performed by
flow cytometry using propidium iodide staining. Percentages of G1 and G2/M cell populations were determined using the ModFit software. C)
Expression of HA-Vpr and p24 was monitored by western blot using specific monoclonal antibodies. Actin was detected using a rabbit polyclonal
antibody. D) HEK293T cells were transfected as in B). Two days after transfection, cells were lysed and subjected to anti-HA immunoprecipitation as
described in Materials and Methods. HA-Vpr, p24 or VPRBP levels were evaluated in cell lysates and immunocomplexes. HA-Vpr and p24 were
detected using specific monoclonal antibodies. VPRBP was detected using a rabbit polyclonal antibody.
doi:10.1371/journal.ppat.1001080.g005
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chromatin-bound factors detected at DNA repair sites suggests
that this tethering co-factor could be a chromatin-bound protein
or structure or DNA itself. To assess this possibility, HeLa cells
were first transiently transfected with an empty plasmid or a
plasmid expressing HA-Vpr and cells were lysed with 0.5% Triton
X-100, resulting in the release of soluble proteins. Treatment of
Triton-insoluble cellular material, including chromatin, with
microccocal nuclease resulted in the solubilization of chromatin-
bound cellular proteins including RPA70 (replication protein A1,
70 kDa) (data not shown) and histone 3 (Figure 8A). These
proteins were not detected when cell extracts were incubated in
buffer without microccocal nuclease. Importantly, chromatin
extracts were not contaminated with cytoplasmic proteins as
revealed by the absence of GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) (Figure 8A). Using this system, we found that a
fraction of HA-Vpr was released in extracts treated by microccocal
nuclease but not with buffer alone, indicating that Vpr associates
with chromatin directly or indirectly via other proteins (Figure 8A).
A specific association of a fraction of endogenous VPRBP with
chromatin was also observed in presence and in absence of Vpr
(Figure 8A). To determine whether the defects of foci formation
observed with C-terminal mutants of Vpr would correlate with a
defect in chromatin association, we analyzed the capacity of
several Vpr mutants to associate to chromatin in HeLa cells.
Interestingly, both Vpr (R80A) and a C-terminal deletion mutant
(Vpr 1–78) showed a drastic reduction in their association to
chromatin (Figure 8B). Of note, Vpr (Q65R) (Figure 8B) and Vpr
(H71R) (data not shown) also failed to associate with chromatin,
possibly explaining their unexpected incapacity to form foci. In
contrast, knockdown of VPRBP did not significantly alter the
affinity of Vpr for chromatin (Figure 8C), suggesting that VPRBP
does not contribute to this association and that the absence of
chromatin association with the Q65R and H71R mutants is not
due to its impaired binding to VPRBP. Therefore, the ability of
Vpr to form foci correlates with its ability to associate with
chromatin.
Vpr and VPRBP interact on chromatin
Co-localization of Vpr nuclear foci with VPRBP and the
association of both proteins to chromatin suggest that they might
interact on chromatin. To evaluate this possibility, we transfected
HeLa cells with an empty plasmid or a plasmid expressing HA-Vpr
and performed anti-HA immunoprecipitations on proteins released
from chromatin by microccocal nuclease (Figure 9A). Interestingly,
we could detect co-immunoprecipitation of endogenous VPRBP
specifically in cells extracts containing HA-Vpr, in the soluble
fraction as well as in the chromatin fraction (Figure 9A). Deletion of
the C-terminal domain of Vpr abrogated its interaction with
VPRBP on chromatin but not in the soluble fraction (Figure 9B),
demonstrating the specificity of these interactions. These data
suggest that Vpr interacts with VPRBP on chromatin. Importantly,
histone 3 did not co-immunoprecipitate with HA-Vpr in the
chromatin fraction (Figure 9A). Moreover, treatment with high
concentrations of ethidium bromide during the immunoprecipita-
tion, a treatment that displace proteins from DNA [47], did not
disrupt the Vpr-VPRBP interaction in the soluble fraction as well as
on chromatin (Figure 9B), thus excluding the possibility that the
observed Vpr-VPRBP interaction was mediated by incompletely
digested chromatin fragments.
Vpr foci are highly mobile long-lasting nuclear bodies
Nuclear bodies stably or transiently associating with chromatin
are generally dynamic structures, either in mobility or in stability.
For instance, PML bodies display varying levels of mobility in the
nucleus. Conversely, DNA repair foci show limited mobility but
can rapidly form in response to genotoxic stress and can
disassemble following checkpoint recovery [48,49,50]. To inves-
tigate the possible dynamic nature of Vpr nuclear foci, we
performed time-lapse confocal microscopy in living HeLa cells
expressing eYFP-Vpr. Strikingly, observation of eYFP-Vpr foci for
two minutes (at two-second intervals) revealed that these were
highly mobile structures (Figure 10A; Videos S1 and S2).
Software-assisted tracking of over fifty Vpr foci (Figure 10B and
Figure 6. Sooty mangabey Vpr but not Vpx forms nuclear foci. HeLa cells were transfected with plasmids expressing sooty mangabey HA-
tagged Vpr (HA-Vpr sm) or Vpx (HA-Vpx sm). Two days after transfection, cells were fixed, permeabilized, and stained with antibodies against HA (red)
and nucleoporin (blue). Images were acquired by confocal microscopy. Images shown are representative of multiple fields. Averages of the number
of Vpr nuclear foci (VNF) per cell and corresponding standard deviations are shown.
doi:10.1371/journal.ppat.1001080.g006
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PLoS Pathogens | www.plospathogens.org 10 September 2010 | Volume 6 | Issue 9 | e1001080Figure 7. Analysis of the self-affinity of wild type Vpr and mutants. A) HEK293T cells were either co-transfected with plasmids expressing
Rluc and eYFP or co-transfected with plasmids expressing Rluc-Vpr (WT) or Rluc-Vpr (Q65R), or Rluc-Vpr (R80A) and eYFP-Vpr (WT) or eYFP. Two days
later, cell lysates were resolved by SDS-PAGE and protein expression was determined by western blot using rabbit polyclonal antibodies directed
against Vpr and GFP. A non-specific band, depicted by the asterisk, was used as loading control. B) BRET saturation assays were performed with live
HEK293T cells. A plasmid expressing Rluc-Vpr (WT), Rluc-Vpr (Q65R) or Rluc-Vpr (R80A) (BRET donor) was co-transfected with increasing concentration
of a plasmid expressing eYFP-Vpr (BRET acceptor) or eYFP (non-specific control). Forty-eight hours post-transfection, energy transfer was initiated by
addition of the cell-permeable renilla luciferase substrate coelenterazine H. Donor saturation curves were obtained by measuring BRET in presence of
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0.05 mm/min to 8.30 mm/min for an average of 0.73 mm/min
(SD=1.00 mm/min; median=0.30 mm/min). The mobility of
Vpr foci was not dependent on the presence of VPRBP since its
knockdown (Figure 10C) did not significantly alter their dynamic
behavior (average rate of displacement of 0.85 mm/min for
VPRBP siRNA vs 0.92 mm/min for scrambled siRNA; P=0.78).
Because some eYFP-Vpr foci seemingly appeared and disappeared
during the course of these observations, we performed time-lapse
spinning-disk microscopy analyses to evaluate whether these foci
were translating in and out of the focal plane or instead assembling
and disassembling. Tracking of eYFP-Vpr nuclear foci for
15 minutes at intervals of 5 seconds highlighted translational
movements in the three axes (Figure S6A). Moreover, these
analyses did not reveal any apparition or disappearance of nuclear
foci (data not shown), suggesting that these are structurally stable.
Similar results were obtained from observations over longer
periods of time (30 minutes). Monitoring of the mean fluorescence
of eYFP-Vpr in foci showed relatively stable signal over time
(Figure S6A, right panel). Some transient fluctuations in
fluorescence were however detected. To determine if these
fluctuations could be the result of quick exchange of Vpr
molecules in and out of nuclear foci, we performed fluorescence
recovery after photobleaching (FRAP) analyses on eYFP-Vpr foci
(Figure S6B). Photobleaching of eYFP-Vpr foci did not however
lead to any fluorescence recovery even after an extensive period of
time (350 seconds), suggesting that the inter-exchange of Vpr
molecules is minimal.
Overall, our results suggest that Vpr would associate to
chromatin-bound nuclear foci via its C-terminus. These would
serve as a mobile scaffold to recruit the DDB1-CUL4A (VPRBP)
E3 ubiquitin ligase to induce the ubiquitination and degradation of
a chromatin-bound substrate, resulting in DNA damage or
replication stress.
Discussion
Our results show that Vpr mainly localizes to the nucleus in
transformed epithelial cells, such as HeLa and HEK293T cells, as
well as in primary CD4+ T-lymphocytes (Figure 1 and data not
shown). We noticed that the localization of Vpr in HeLa cells
closely resembles that observed in primary CD4+ T-lymphocytes,
prompting us to select this cellular model for most of our study.
Moreover, we found that ectopically expressed HA-tagged Vpr
had a subcellular localization similar to that of the native protein
(Figure S1A). In infected cells, the nuclear localization of Vpr
appears transient because Gag interacts with Vpr to package the
protein into assembling viral particles (Figures S1B and S1C). Our
localization data show that Vpr can form nuclear punctuate
structure that we termed Vpr nuclear foci (Figure 1), as was
reported previously by Lai and colleagues [17]. It is noteworthy
that these foci are not readily apparent and require careful
calibration of gain to be observed (data not shown). Importantly,
we observed a strong co-localization of Vpr with VPRBP in the
nucleus, particularly in these foci. In situ proximity ligation assays
confirmed the close proximity of the two proteins in these foci
(Figure 1C), suggesting that Vpr interacts with the E3 ubiquitin
ligase at the levels of these punctuate structures. In contrast to the
observations of other investigators [37,38,39,40,41,42], we did not
observe a significant accumulation of Vpr at the nuclear
membrane in these cell types. Several technical reasons might
explain these discrepancies, including cell types, levels of
expression, fixation and permeabilization conditions, or the tag
used. Indeed, we did observe an enrichment of eYFP-Vpr at the
nuclear membrane of Hela cells (Videos S1 and S2).
We obtained several lines of evidence demonstrating that Vpr
nuclear foci are involved in Vpr-mediated G2 arrest. First, we
observed a partial co-localization between these foci and RPA32,
53BP1 and c-H2AX, which are usually detected at DNA repair
sites (Figures 2 and S4). Similar results were obtained by Lai and
colleagues with c-H2AX [17]. Secondly, C-terminal mutants of
Vpr defective for G2 arrest failed to induce formation of Vpr foci
despite their nuclear localization (Figure 4). Thirdly, cytoplasmic
sequestration of Vpr by overexpression of Gag inhibited G2 arrest
as well as foci formation (Figure 5). Fourthly, only Vpr from sooty
mangabey SIV but not its G2 arrest-defective paralog Vpx was
able to form these foci (Figure 6). Lastly, the reduced number of
foci formed by sooty mangabey Vpr in comparison to HIV-1 Vpr
correlated with reduced G2 arrest activity in human cells (data not
shown and [9]). All these results suggest that formation of foci is
linked to G2 arrest. Moreover, these results also suggest that
nuclear localization of Vpr is required but not sufficient to induce
formation of these foci. Our results and conclusions are in contrast
with previous reports, including one of ours, describing cytoplas-
mic mutants of Vpr that retain their G2 arrest activity
[30,36,37,41]. We had reported over a decade ago that the
V57L and R62P mutations induced the relocalization of Vpr to
the cytoplasm, while these mutants were still able to induce G2
arrest [36]. However, careful re-examination of the localization of
these mutants showed that both mutants could localize to the
nucleus to some degree. While, the V57L mutant had a reduced
capacity to form foci, the R62P mutant was completely defective
for foci formation (Figure S7A). The reduced capacity of V57L
mutant and the defect of the R62P mutant in foci formation
correlated, respectively, with attenuation and abrogation of G2
arrest (Figure S7B). These differences between our present
localization data and our previously published results can probably
be explained by improved imaging sensitivity, whereas the
discrepancies in G2 arrest activity are unclear. Nevertheless, these
results highlight an important technical limitation in these types of
localization experiments: lack of detection in a subcellular
compartment does not necessarily indicate an absence of protein.
Correlation between G2 arrest and formation of Vpr nuclear
foci implies that the formation of these foci could either be an early
event leading to G2 arrest or could be a consequence of this G2
arrest. We observed that treatment with the ATR/ATM inhibitor
a fixed quantity of donor and increasing amounts of acceptor. The x-axis shows the ratio between the fluorescence (520 nm) of the acceptor (YFP-
YFP0, where YFP0 is the fluorescence value in cells expressing the BRET donor alone) and the luminescence (475 nm) of the donor. BRET ratios (y-axis)
were calculated as described in Materials and Methods. BRETmax is the maximal BRET signal reached at saturation. BRET50, which represents the
concentration (fluorescence/luminescence) of acceptor giving 50% of BRETmax, is a measure of the relative affinity of each fusion protein. Self-
affinities relative to wild type are depicted in the graph. Curves shown represent the means 6 standard deviations of results from one representative
experiment performed in duplicate. The curves were generated by non-linear regression, in which a single binding site was assumed using the Sigma
Plot software v.10. C) HeLa cells were co-transfected with plasmids expressing eYFP-Vpr and HA-Vpr WT, R80A, or Q65R. Two days after transfection,
cells were fixed, permeabilized, and stained with antibodies against HA (red). EYFP-Vpr was detected by direct fluorescence (green) and DAPI (4,6-
diamidino-2-phenylindole) was used to highlight the nuclei (cyan). Images were acquired by confocal microscopy. Images shown are representative
of multiple fields.
doi:10.1371/journal.ppat.1001080.g007
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indicating that these foci likely constitute an early event in the
induction of G2 arrest by Vpr. In fact, formation of Vpr foci was
not affected by an almost complete knockdown of VPRBP
suggesting that their formation is independent of the recruitment
of the E3 ligase complex and would therefore precede ubiquitina-
tion and degradation of the putative G2 arrest substrate (Figures 3B
and S4). In contrast, we found that the Q65R mutant of Vpr was
unable to form foci. In addition to a reduced affinity for VPRBP
[19,20,22], this mutation also leads to other defects including
accumulation of Vpr in the cytoplasm (Figure 4), reduced
dimerization efficiency (Figure 7), and absence of binding to
chromatin (Figure 8B), indicating that the Q65R mutation has
pleiotropic effects on the functions of Vpr. Yet, this mutation did
not prevent efficient packaging of Vpr into virions [12]. Cautions
should thus be used when interpreting results obtained with this
mutant. Despite these pleiotropic defects, we cannot completely
exclude the possibility that, in addition to the C-terminal domain,
Figure 8. Association of Vpr with chromatin correlates with the formation of nuclear foci. A) HeLa cells were transfected with plasmids
expressing HA-tagged Vpr (WT) or an empty plasmid used as negative control. Forty-eight hours after transfection, cells were harvested and lysed
with 0.5% Triton X-100. The soluble fraction was used as input control (Soluble). Insoluble debris containing chromatin was treated with microccocal
nuclease (+MNase) or with buffer alone (2MNase). The resulting solubilized fractions and input controls were resolved by SDS-PAGE and analyzed by
western blot. Specific monoclonal antibodies were used to detect GAPDH (cytoplasmic marker) and HA-Vpr. Histone 3 (chromatin marker) and VPRBP
were detected using rabbit polyclonal antibodies. * Denotes a non-specific band detected with the anti-HA antibody. B) HeLa cells were transfected
with plasmids expressing HA-tagged Vpr (WT), Vpr (Q65R), Vpr (R80A), and Vpr (1–78). Cell extracts were processed and analysed as in A). C) HeLa
cells were first transfected with scrambled siRNA or siRNA targeting VPRBP. Twenty-four hours after transfection, cells were transfected with a plasmid
expressing HA-Vpr (WT) or an empty plasmid as negative control. Cell extracts were processed and analyzed as in A).
doi:10.1371/journal.ppat.1001080.g008
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chromatin association.
Given that Vpr foci containing VPRBP partially co-localize
with chromatin-bound protein such as RPA32 and that Vpr
associates with DNA in vitro [51] and in vivo (Figure 8A and [17]),
we propose that Vpr might be able to target a chromatin-bound
cellular factor. In support of this hypothesis, Lai et al. showed that
in situ nuclease treatment of Vpr-expressing cells eliminates Vpr
nuclear foci [17], suggesting that Vpr nuclear foci are anchored to
chromatin. Deletion of the C-terminal domain of Vpr drastically
reduced foci formation (Figure 4) and its chromatin association
(Figure 8B). Similar results were obtained by Lai and colleagues
[17]. Moreover, mutation of the arginine at position 80 did not
affect direct binding to nucleic acids in vitro [51] but nevertheless
impaired association to chromatin in vivo (Figure 8B), implying that
a cellular factor rather than a direct binding to DNA would be
implicated in association to chromatin. This cellular factor does
not appear to be VPRBP since its knockdown did not significantly
reduce the binding of Vpr to chromatin (Figure 8C). Moreover, we
also observed protein-protein interaction between Vpr and
VPRBP on chromatin (Figure 9), suggesting that Vpr would be
able to recruit the E3 ligase DDB1-CUL4A (VPRBP) onto
chromatin.
Strikingly, analysis of Vpr nuclear foci by time-lapse microscopy
(Figures 10 and S5, Videos S1 and S2) revealed that these foci
moved rapidly in the nucleus (average of 0.73 mm/min). As a
comparison, passive diffusion of chromatin-bound DNA repair
foci was estimated at 1–2 mm per 6 hours [52]. These results
suggest that instead of stably interacting with chromatin, Vpr
nuclear foci would do so in a dynamic manner, allowing
movement of the foci along chromatin strands. One possible
model to integrate all our results is that Vpr could interact with its
putative substrate via its C-terminus in these chromatin-bound
nuclear foci and could recruit the DDB1-CUL4A(VPRBP) E3
ligase to degrade the substrate, thus preventing its potential role in
DNA replication or DNA repair. This model implies that Vpr
Figure 9. Vpr and VPRBP associate on chromatin. A) HeLa cells were transfected with a plasmid expressing HA-tagged Vpr (WT) or an empty
plasmid used as negative control. Soluble and chromatin-bound fractions were isolated and were subjected to anti-HA immunoprecipitation as
described in Materials and Methods. B) HeLa cells were transfected with a plasmid expressing HA-tagged Vpr (WT) or Vpr (1–78). Soluble and
chromatin-bound fractions were isolated and subjected to anti-HA immunoprecipitation as described in Materials and Methods. Half of the
immunoprecipitations (lanes 8, 10, 12, and 14) were conducted in presence of 25 mg/ml ethidium bromide (EtBr) to displace proteins from DNA. For
both panels, input controls and immunoprecipitates were resolved by SDS-PAGE and analyzed by western blot. Specific monoclonal antibodies were
used to detect GAPDH (cytoplasmic marker) and HA-Vpr. Histone 3 (chromatin marker) and VPRBP were detected using rabbit polyclonal antibodies.
* Denotes a non-specific band detected with the anti-HA antibody.
doi:10.1371/journal.ppat.1001080.g009
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these nuclear bodies and that the subsequent degradation of this
substrate would not exclude Vpr from these structures nor would it
disrupt them. Another possibility is that Vpr would interact with a
nuclear foci-associated co-factor via its C-terminus and would
utilize these mobile structures to scan chromatin for its putative
substrate. This second model requires that either Vpr possesses an
additional functional domain mediating the interaction with the
substrate or that Vpr targets VPRBP’s own natural substrates.
Irrespective of the above models, as was recently documented, the
substrate would be covalently modified with classical K48-linked
polyubiquitin chains in a DDB1-CUL4A (VRPBP)-dependent
manner and degraded by the proteasome [26]. Moreover, multiple
units of the putative substrate/co-factor are probably required in
these nuclear bodies in order for Vpr to accumulate in these
structures. Even though Vpr multimerization was shown to occur
in these foci (Figure 7), it is unlikely that it would play a major role
in this process given that the L23F mutation was previously shown
to block dimerization [40,53] but did not significantly affect foci
formation and induction of G2 arrest (Figure S5). Similar
conclusions were also previously obtained with the I70S mutation
which was shown to block dimerization without affecting the
induction of G2 arrest [30]. It however remains unclear whether
Vpr would bind VPRBP before or after localizing to these foci,
particularly when considering the important level of interaction
observed in the Triton-soluble fraction (Figure 9). Moreover, the
significance of the partial co-localization observed between Vpr
and DNA repair foci containing RPA32, 53BP1 and c-H2AX
(Figures 2 and S4) is also unclear. On one hand it could mean that
degradation of the chromatin-bound substrate would induce DNA
damage or DNA replication stress in situ and that this partial co-
localization would be explained by the high mobility of Vpr foci.
On the other hand, we cannot exclude the possibility that
degradation of the substrate could induce global genomic
instability and that this partial co-localization would only be
fortuitous.
Overall, our results show that Vpr forms highly mobile nuclear
foci containing VPRBP and demonstrate that formation of these
structures constitutes a critical early event in the induction of DNA
damage/stress and G2 arrest by Vpr. The characterization of
these chromatin-bound nuclear foci hijacked by Vpr will likely
contribute to better delineate the mechanism by which Vpr
activates ATR and induces G2 arrest. Importantly, our results
further suggest that the putative cellular substrate targeted by Vpr
is likely to be a chromatin-associated protein.
Materials and Methods
Ethics statement
Peripheral blood samples were obtained from adult donors who
gave written informed consent under research protocols approved
by the research ethics review board of the Institut de recherches
cliniques de Montreal.
Cells, antibodies, and other reagents
HeLa and HEK293T cells were cultured as previously
described [54]. Primary CD4+ T-lymphocytes were isolated and
cultured as previously described [26]. The development of the
HEK293T cell line stably depleted of VPRBP was described
previously [26]. Caffeine and DAPI (49,6-Diamidino-2-phenylin-
dole) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
SiRNA targeting VPRBP (siGenome SMARTpool M-021119-00)
and scrambled control siRNA (non-targeting siRNA #2) were
obtained from Dharmacon (Chicago, IL, USA). The anti-HA
(clone 12CA5) and anti-p24 (catalog no. HB9725) monoclonal
antibodies were produced from hybridomas obtained from the
American Type Culture Collection (Manassas, VA, USA). The
monoclonal antibody against Vpr (clone 8D1) was a kind gift of Dr
Y. Ishizaka (International Medical Center of Japan, Tokyo, Japan)
[55]. The following commercially available antibodies were used:
mouse anti-nucleoporin (Abcam, Cambridge, MA, USA), mouse
anti-RPA70 (Abcam), rabbit anti-53BP1 (Abcam), rabbit anti-
GAPDH (Cell Signaling Technology, Danvers, MA, USA), rabbit
anti-H3 antibodies (Abcam) rabbit anti-phospho RPA32 (S4/S8)
(Bethyl Laboratories, Montgomery, TX, USA), rabbit anti-
VPRBP (Accurate Chemical and Scientific Corporation, West-
bury, NY, USA), rabbit anti-actin (Sigma-Aldrich, St. Louis, MO,
USA), mouse anti-phosphoS139-H2AX (clone JBW301)(Upstate,
Millipore, Billerica, MA, USA), mouse FITC-conjugated anti-p24
(clone KC57, Beckman Coulter Canada, Mississauga, Ontario,
Canada), mouse anti-SC35 (Sigma-Aldrich), and mouse anti-PML
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). All fluoro-
chrome-conjugated secondary antibodies were obtained from
Molecular Probes (Invitrogen, San Diego, CA, USA).
Plasmid construction
SVCMV-Vpr (WT), SVCMV-Vpr (L23F), SVCMV-HA-Vpr
(WT), SVCMV-HA-Vpr (V57L), SVCMV-HA-Vpr (R62P),
SVCMV-HA-Vpr (Q65R), SVCMV-HA-Vpr (H71R), SVCMV-
HA-Vpr (R80A), SVCMV-HA-Vpr (S79A), SVCMV-HA-Vpr
(1–86), SVCMV-HA-Vpr (1–78), and SVCMV-VSV-G were previ-
ously described or were constructed by PCR as previously des-
cribed [19,32,46]. Plasmids pCDNA3.1_eYFP-MCS(MB) and
pCDNA3.1_Rluc-MCS(MB) for the expression of eYFP and renilla
luciferease (Rluc) N-terminal fusion proteins were kind gifts of M. Baril
and D. Lamarre [56]. Wild type Vpr was amplified by PCR from
SVCMV-HA-Vpr (WT) and subcloned into pCDNA3.1_eYFP-
MCS(MB) and pCDNA3.1_Rluc-MCS(MB) to generate respectively
pCDNA3.1-eYFP-Vpr(WT) and pCDNA3.1-Rluc-Vpr (WT). Vpr
(R80A) and Vpr (Q65R) were subcloned into pCDNA3.1_Rluc-
MCS(MB) to generate pCDNA3.1-Rluc-Vpr (R80A) and pCDNA3.1-
Rluc-Vpr (Q65R) using the same strategy. The lentiviral vector pWPI
as well as the packaging plasmid psPAX2 expressing Gag-Pol, Tat and
Rev were obtained from Dr. D. Trono (School of Life Sciences, Swiss
Institute of Technology, Lausanne, Switzerland). The lentiviral vector
pWPI-HA-Vpr (WT) transducing HA-tagged Vpr and GFP was
generated from the parental vector pWPI using a strategy described
previously [19]. The plasmids expressing sooty mangabey HA-tagged
Figure 10. Vpr nuclear foci are mobile nuclear bodies. A) HeLa cells were transfected with a plasmid expressing eYFP-Vpr WT. Two days after
transfection, the location of eYFP-Vpr was monitored by time-lapse confocal microscopy in living cells. Images were acquired with a 636objective at
intervals of 2 seconds for two minutes. Representative images taken at time points spanning the period of acquisition are shown. The initial positions
of Vpr foci are depicted by colored circles. The actual positions of foci are indicated with colored arrows. B) Vpr foci in images acquired in A) were
tracked using the Volocity software v.5.2.1. Movement tracks of foci are depicted in colors on the picture. Rates of displacement for each focus are
indicated at the right of the picture. Please note that some foci could not be tracked for the full time of acquisition because they were migrating out
of the focal plane. C) HeLa cells were first transfected with scrambled siRNA or siRNA targeting VPRBP. Twenty-four hours after transfection, cells were
transfected with a plasmid expressing eYFP-Vpr. The location of eYFP-Vpr foci was determined as in A) and rates of displacement were calculated as
in B). Rates of displacement of individual foci are shown in a dot plot. Averages of displacement rates are indicated as horizontal bars.
doi:10.1371/journal.ppat.1001080.g010
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France) [4]. The infectious molecular clones HxBru (Vpr-), HxBru
(HA-Vpr), and HxBru Vpr L23F, were described previously
[26,32,57]. The HxBru VprWT LF/PS molecular clone with
mutations (L44P, F45S) in the p6 domain of Gag disrupting interaction
with Vpr was described previously [58].
Production and titration of viruses and lentiviral vectors
The production and titration of VSV-G-pseudotyped HIV
particles and lentiviral vectors were performed as described
previously [19,46].
Transfection, transduction and infection
HeLa cells were transfected using the Lipofectamine 2000
reagent (Invitrogen Canada, Burlington, Ontario, Canada)
according to the manufacturer’s instructions. HEK293T cells
were transfected by a standard calcium phosphate precipitation
protocol. SiRNA were transfected using Lipofectamine RNAi Max
(Invitrogen Canada, Burlington, Ontario, Canada), according to
the manufacturer’s instructions. HeLa cells were transduced with
the lentiviral vectors WPI and WPI-HA-Vpr in presence of 8mg/
ml polybrene at a multiplicity of infection of 0.5 to 2.5, as
indicated for each experiment. Primary CD4+ T-lymphocytes
were transduced by spinoculation at a multiplicity of infection of 1.
Briefly, cells were mixed with lentiviral vector particles in presence
of 8mg/ml polybrene and centrifuged for 2 hours at 1200g. HeLa
cells were infected, in presence of 8 mg/ml polybrene, with VSV-
G-pseudotyped HIV-1 viruses at a concentration of 100 cpm/cell
or at a MOI of 1.0, as indicated for each experiment.
Fluorescence microscopy and live-cell imaging
Fifty thousand HeLa cells were seeded on cover slips in 24-well
plates. Cells were transfected, transduced, or infected as indicated
for each experiment. Two days later, cells were processed for
fluorescence immunohistochemistry and laser-scanning confocal
microscopy as previously described [59]. For analysis of CD4+
primary T-lymphocytes, 5610
5 cells were first adhered on poly-
Lysine-treated coverslips for two hours in PBS and then processed
as described [59]. Quantification of Vpr nuclear foci was
performed in at least 30 randomly selected cells by manual
counting. Time-lapse confocal microscopy was performed on
living cells in a PeCON environmental chamber maintained at
37uC and 5% CO2. Images were acquired using a Zeiss LSM 710
system with the ZEN 2009 software. Spinning-disk confocal
microscopy was performed on living cells using a Quorum
WaveFX-X1 spinning-disc confocal system (Quorum Technolo-
gies Inc, Guelph, Ontario, Canada). Cells were maintained at
37uCi n5 %C O 2 in a Live Cell Instruments Chamlide TC
environmental chamber. Images were acquired with a Hama-
matsu ImagEM C9100-13 camera using the Metamorph software.
FRAP (fluorescence recovery after photobleaching) experiments
were conducted using the Quorum WaveFX-X1 spinning-disc
confocal system equipped with a Photonic Instruments Mosaic
405 nm laser. Images were processed using AxioVision v.4.7.
Videos were generated with the ZEN 2009 software. Software-
assisted fluorescence quantification and tracking of Vpr foci was
performed with the Volocity software v.5.2.1. Statistical analysis
was performed using Sigma Plot software v.10.
In situ proximity ligation assay
In situ proximity ligation assays (PLA) were performed using the
Duolink kit 613 (Olink bioscience, Uppsala, Sweden). Briefly,
HeLa cells were transfected with a plasmid encoding HA-Vpr or
an empty plasmid as negative control. At 48h post-transfection, the
cells were cytospun for 7 min at 1,100 rpm onto a glass slides and
were fixed and permeabilized as described above. The fixed cells
were incubated with the following antibodies: mouse monoclonal
antibody against HA (clone 12CA5) or Vpr (a gift from Dr Y.
Ishizaka. The antibody was shown to recognize both Vpr WT and
Q65R [12]) and a rabbit polyclonal antibody against VPRBP
(Accurate Chemical and Scientific Corporation). The Duolink
system provides oligonucleotide-labeled secondary antibodies
(PLA probes) to each of the primary antibodies that, in
combination with a DNA amplification-based reporter system,
generate a signal only when the two primary antibodies are in
close proximity. The signal from each detected pair of primary
antibodies was visualized as a spot (please see the manufacturer’s
instructions for more details). Nuclei were delineated using
Hoechst 33342.
Cell cycle analysis
Cell cycle analysis was performed using propidium iodide
staining and flow cytometry as previously described [12,19].
Immunoprecipitation and western blot
Immunoprecipitations using anti-HA-conjugated agarose beads
were performed as previously described [26]. Analysis of proteins
by western blot was performed as previously described [26].
Bioluminescence resonance energy transfer (BRET) assays
HEK293T cells were transfected in 24-well plates with 10
ng of the BRET donor plasmids pCDNA3.1_Rluc-MCS(MB),
pCDNA3.1-Rluc-Vpr (WT), pCDNA3.1-Rluc-Vpr (R80A) or
pCDNA3.1-Rluc-Vpr (Q65R) and increasing concentration (0 to
500 ng) of the BRET acceptor plasmids pCDNA3.1_eYFP-
MCS(MB) or pCDNA3.1-eYFP-Vpr (WT) using Lipofectamine
2000. Two days after transfection, cells were harvested, washed
twice in PBS, and aliquoted in two wells of a 96-well plate (Costar
3917). Total eYFP fluorescence was measured with an excitation
wavelength of 485 nm and an emission wavelength at
520610 nm. BRET was initiated by adding 5mM of the renilla
luciferase substrate coelenterazine H (Prolume Ltd., Lakeside, AZ,
USA). Luminescence was then measured 10 minutes later at
475615 nm and BRET fluorescence was measured at
535615 nm. All measurements were performed on a PheraStar
microplate reader (BMG Labtech, Cary, NC, USA). BRET ratios
were calculated using this formula: (emission at 535 nm/emission
at 475 nm)-(background emission at 535nm/background emission
at 475 nm), as previously described [60].
Chromatin binding assays
Cells were lysed in triton lysis buffer (50 mM Tris pH 7.5,
150 mM NaCl, 0.5% Triton X-100, and complete protease
inhibitors cocktail (Roche) for 15 minutes. Insoluble cell debris,
including chromatin, was pelleted by centrifugation (2500g for
10 minutes). The supernatant was harvested and represented the
soluble input control. Pellets were washed once with nuclease
buffer (50 mM Tris pH 8.0, 5 mM CaCl2, and 100 mg/ml BSA),
split in two, and resuspended in nuclease buffer alone or nuclease
buffer containing 200 U/ml microccocal nuclease (New England
Biolabs, Ipswich, MA, USA). Pellets were incubated for 30 min-
utes on ice and then centrifuged at 12000g for 10 minutes. The
supernatant was harvested and represented the chromatin-bound
fraction. The corresponding supernatant obtained in absence of
nuclease was used to control for non-specific release. For
immunoprecipitation experiments, soluble and nuclease-treated
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agarose beads (Sigma-Aldrich) for 2h at 4C. In some experiments,
immunoprecipitations were supplemented with 25 mg/ml ethi-
dium bromide to displace proteins from DNA [47].
Supporting Information
Figure S1 Native Vpr and virally-encoded Vpr form nuclear
foci. A) HeLa cells were transfected with plasmids expressing
native Vpr. Two days after transfection, cells were fixed,
permeabilized, and stained with monoclonal antibodies against
Vpr (clone 8D1) and analyzed by confocal microscopy. B) HeLa
cells were infected with VSV-G-pseudotyped viruses defective for
Vpr expression (HxBru Vpr-) or expressing HA-tagged Vpr
(HxBru HA-Vpr) at 100 cpm/cell. Two days after infection, cells
were fixed, permeabilized, and stained with antibodies against HA
(red), nucleoporin (blue) and VPRBP (green). Images were
acquired by confocal microscopy. Images shown are representative
of multiple fields that encompass minor and major phenotypes. C)
Hela cells were infected at a MOI of 1.0 with VSV-G-pseudotyped
viruses expressing Vpr WT (WT) or Vpr L23F (L23F) or
expressing Vpr WT while harboring the L44P,F45S mutations
in the p6 domain of Gag (LF/PS). Two days after infection, cells
were fixed, permeabilized, and stained with monoclonal antibodies
against Vpr (red) and nucleoporin (blue). Images were acquired by
confocal microscopy. Images shown are representative of multiple
fields.
Found at: doi:10.1371/journal.ppat.1001080.s001 (2.10 MB PDF)
Figure S2 Vpr Q65R is not in close proximity to VPRBP. HeLa
cells were transfected with plasmids expressing GFP alone (WPI)
or co-expressing GFP and Vpr WT (WPI-Vpr WT) or GFP and
Vpr Q65R (WPI-Vpr Q65R). In situ proximity ligation assay
(PLA) was performed on HeLa cells stained with a mouse
monoclonal antibody against Vpr and a rabbit polyclonal antibody
against VPRBP. A flurochrome-labeled probe (red) was then used
to reveal locations of close proximity between the two proteins in
GFP-expressing cells (green). Hoechst 33342 was used to highlight
nuclei (cyan). Images were acquired by confocal microscopy with a
636objective. Images shown are representative of multiple fields.
Found at: doi:10.1371/journal.ppat.1001080.s002 (1.58 MB PDF)
Figure S3 Vpr nuclear foci do not co-localize with SC35 or
PML. HeLa cells were transduced with lentiviral vectors
expressing HA-Vpr. Two days after transduction, cells were fixed,
permeabilized, and stained with A) antibodies against HA (red)
and SC35 (green) or B) antibodies against HA (red) and PML
(green). Images were acquired by confocal microscopy. Images
shown are representative of multiple fields.
Found at: doi:10.1371/journal.ppat.1001080.s003 (0.63 MB PDF)
Figure S4 Depletion of VPRBP inhibits formation of DNA
repair foci but not of Vpr nuclear foci. A) HeLa cells were
transfected with control scrambled siRNA or siRNA targeting
VPRBP. Twenty-four hours after transfection, cells were trans-
duced with a lentiviral vector expressing HA-Vpr. One day after
transduction, cells were fixed, permeabilized, and stained with
antibodies against HA (red), c-H2AX (green) and 53BP1 (blue).
DAPI was used to highlight nuclei (cyan). Images were acquired by
confocal microscopy. Images shown are representative of multiple
fields. Yellow arrows highlight examples of punctuate co-
localization. B) The numbers of c-H2AX or 53BP1 foci per cell
in A) were quantified and cells with greater than 10 foci were
considered positive. Results depicted in the graph are the means of
three independent experiments. Error bars represent standard
deviations.
Found at: doi:10.1371/journal.ppat.1001080.s004 (1.28 MB PDF)
Figure S5 Analysis of the effect of blocking the Vpr-p6
interaction on Vpr nuclear foci formation and induction of G2
arrest. A) HeLa cells were transfected with a plasmid expressing
Vpr L23F. Two days after transfection, cells were fixed,
permeabilized, and stained with monoclonal antibodies against
Vpr (clone 8D1) and nucleoporin (blue) and analyzed by confocal
microscopy. B) HeLa cells were co-transfected with the packaging
plasmid psPAX2 encoding Gag-Pol, Tat, and Rev and with
plasmids expressing Vpr WT or Vpr L23F. Two days after
transfection, cells were fixed, permeabilized, and stained with
antibodies against Vpr (red), nucleoporin (blue) and p24 (green).
Images were acquired by confocal microscopy. Images shown are
representative of multiple fields. C) HEK293T cells were
cotransfected with plasmids expressing GFP, Vpr (WT or L23F)
and Gag-Pol or with an empty plasmid control as indicated. Forty-
eight hours after transfection, cell cycle analysis was performed by
flow cytometry using propidium iodide staining. Percentages of G1
and G2/M cell populations were determined using the ModFit
software. D) Hela cells were infected at a multiplicity of infection
of 1.0 with VSV-G-pseudotyped viruses defective for Vpr
expression (HxBru Vpr-) or expressing Vpr WT in the context
of wild type p6 (HxBru VprWT) or mutated p6 (HxBru VprWT
LF/PS). Mock-infected cells were used as a negative control.
Forty-eight hours after infection, cell cycle analysis of HIV-1-
expressing cells was performed by flow cytometry using FITC-
conjugated anti-p24 monoclonal antibodies and propidium iodide
staining. Percentages of p24+ cells in G1 and G2/M were
determined using the ModFit software.
Found at: doi:10.1371/journal.ppat.1001080.s005 (2.70 MB PDF)
Figure S6 Vpr nuclear foci are long-lived and display limited
exchange of Vpr molecules. A) HeLa cells were transfected with a
plasmid expressing eYFP-Vpr WT. Two days after transfection,
the location of eYFP-Vpr was monitored by time-lapse spinning-
disk confocal microscopy in living cells. Images were acquired with
a6 0 6 objective at intervals of 5 seconds for 15 minutes. One
hundred and ten Z cross-sections were taken for each time point.
Vpr foci were tracked using the Volocity software v.5.2.1.
Movement tracks of some foci are depicted in color on the
orthogonal sections of the images acquired at time 0. The graph
on the right panel shows mean fluorescence intensity for each
tracked focus over time. B) Hela cells transfected as in A) were
subjected to FRAP (fluorescence recovery after photobleaching)
assays. Regions of interest included photobleached background
(green), photobleached eYFP-Vpr focus (red) and control eYFP-
Vpr focus (blue). Images were acquired by spinning-disk confocal
microscopy at 5 seconds intervals for 400 seconds. After 50 sec-
onds, the indicated regions of interest were partially photo-
bleached to allow detection and tracking of mobile eYFP-Vpr foci.
The graph on the right panel shows mean fluorescence intensity
for each region of interest over time. Results shown are
representative of multiple experiments.
Found at: doi:10.1371/journal.ppat.1001080.s006 (1.06 MB PDF)
Figure S7 Localization and G2 arrest activity of the Vpr
mutants V57L and R62P. A) HeLa cells were transfected with
plasmids expressing HA-tagged Vpr (V57L) and Vpr (R62P).
Forty-eight hours after transfection, cells were fixed, permeabi-
lized, and stained with antibodies against HA (red) and
nucleoporin (blue). Images were acquired by confocal microscopy.
Images shown are representative of multiple fields. 60% of cells
expressing HA-Vpr (V57L) could form nuclear foci while the
remaining 40% displayed perinuclear accumulation with reduced
or absence of nucleoporin staining. 20% of cells expressing HA-
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remaining 80% of cells showed accumulation of Vpr in the
cytoplasm. In all cases, HA-Vpr (R62P) did not form nuclear foci.
B) HEK293T cells were co-transfected with a plasmid expressing
GFP and a plasmid expressing HA-Vpr (WT), HA-Vpr (V57L), or
HA-Vpr (R62P). An empty plasmid was used as negative control
(mock). Forty-eight hours after transfection, cell cycle analysis was
performed by flow cytometry using propidium iodide staining.
Percentages of G1 and G2/M cell populations were determined
using the ModFit software.
Found at: doi:10.1371/journal.ppat.1001080.s007 (2.14 MB PDF)
Video S1 Vpr nuclear foci are mobile nuclear bodies. HeLa cells
were transfected with a plasmid expressing eYFP-Vpr WT. Two
days after transfection, the location of eYFP-Vpr was monitored
by time-lapse confocal microscopy in living cells. Images were
acquired with a 636 objective at intervals of 2 seconds for two
minutes. The frame rate was accelerated 10 times to facilitate
visualization. Note that the presence of eYFP-Vpr at the nuclear
membrane allows delineation of the nucleus.
Found at: doi:10.1371/journal.ppat.1001080.s008 (8.04 MB AVI)
Video S2 Vpr nuclear foci are mobile nuclear bodies. HeLa cells
were transfected with a plasmid expressing eYFP-Vpr WT. Two
days after transfection, the location of eYFP-Vpr was monitored
by time-lapse confocal microscopy in living cells. Images were
acquired with a 636 objective at intervals of 2 seconds for two
minutes. The frame rate was accelerated 10 times to facilitate
visualization. Note that the presence of eYFP-Vpr at the nuclear
membrane allows delineation of the nucleus.
Found at: doi:10.1371/journal.ppat.1001080.s009 (0.96 MB AVI)
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